nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

12.06.2017 | Original Article – Clinical Oncology

Survival of melanoma patients treated with novel drugs: retrospective analysis of real-world data

verfasst von: Marta Polkowska, Paweł Ekk-Cierniakowski, Edyta Czepielewska, Wojciech Wysoczański, Wojciech Matusewicz, Małgorzata Kozłowska-Wojciechowska

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 10/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Recently, several new drugs have been licensed for advanced melanoma therapy, significantly changing the therapeutic landscape. Ipilimumab and vemurafenib were the first drugs that demonstrated a survival benefit over the long-standing standard therapy with dacarbazine. However, the comparative efficacy of these novel drugs has not been properly assessed yet.

Patients and methods

We conducted a retrospective analysis of all the Polish population treated between January 2012 and October 2016 with one of the following agents: ipilimumab (IPI), vemurafenib (VEM), dabrafenib (DAB), and classic chemotherapy (CTH). The main objective was to assess the overall survival of melanoma patients treated in real-world conditions, taking into account sequences of treatment.

Results

We identified 3397 patients with malignant melanoma treated for the first line and the second line. Patients receiving CTH were significantly older than those treated with the novel drugs. At the same time, the population treated with immunotherapy and targeted therapy was well balanced. Overall survival was significantly better for the novel drugs compared to classic chemotherapy in both lines (for the first line, VEM vs CTH HR = 0.72, 95% CI 0.65–0.81; p < .01, and for the second line, VEM vs CTH HR = 0.78, 95% CI 0.62–0.98; p = .03; IPI vs CTH HR = 0.72, 95% CI 0.62–0.86; p < .01). There was no statistically significant difference for IPI vs VEM; however, subgroup analysis revealed superior results in the case of the CTH–IPI over BRAFi–IPI sequence.

Conclusion

Novel drugs for melanoma provide a significant advantage in survival over classic chemotherapy. Comparative assessment of IPI and VEM indicated no difference, but only immunotherapy-treated patients achieved long-lasting results. Our data on sequential treatment indicate that immunotherapy might be a better option for the first line rather than targeted therapy, but that conclusion requires further studies of the best way to manage the treatment of melanoma patients.

Ackerman A, Klein O, McDermott DF et al (2014) Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer 120:1695–1701CrossRefPubMed

Ascierto PA, Simeone E, Sileni VC et al (2014) Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program. Cancer Invest 32:144–149CrossRefPubMed

Aya F, Fernandez-Martinez A, Gaba L et al (2017) Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma. Clin Transl Oncol 19:119–124CrossRefPubMed

Balch C, Soong S, Gershenwald J et al (2013) Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol 20:3961–3968CrossRefPubMedPubMedCentral

Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–2516CrossRefPubMedPubMedCentral

Dummer R, Hauschild A, Lindenblatt N et al (2015) Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(suppl 5):v126–v132CrossRefPubMed

Eigentler TK, Schlaak M, Hassel JC et al (2014) Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions. J Immunother 37:374–381CrossRefPubMed

Fennira F, Pagès C, Schneider P et al (2014) Vemurafenib in the French temporary authorization for use metastatic melanoma cohort: a single-centre trial. Melanoma Res 24:75–82CrossRefPubMed

Forschner A, Eichner F, Amaral T et al (2017) Improvement of overall survival in stage IV melanoma patients during 2011–2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR). J Cancer Res Clin Oncol 143:533–540CrossRefPubMed

Harding JJ, Catalanotti F, Munhoz RR et al (2015) A retrospective evaluation of vemurafenib as treatment for BRAF-mutant melanoma brain metastases. Oncologist 20:789–797CrossRefPubMedPubMedCentral

Hauschild A, Grob JJ, Demidov LV et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358–365CrossRefPubMed

Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723CrossRefPubMedPubMedCentral

Johnson DB, Pectasides E, Feld E et al (2017) Sequencing treatment in BRAF V600 mutant melanoma: Anti-PD-1 before and after BRAF inhibition. J Immunother 40:31–35CrossRefPubMed

Krzakowski M, Warzocha K, Rutkowski P, et al. (2013) Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych (ed) Czerniaki skóry. Gdańsk, VM Media. http://onkologia.zalecenia.med.pl/pdf/PTOK_2013_09_Czerniaki%20skory_internet10-2014.pdf. Accessed 6 Oct 2014

Larkin J, Del Vecchio M, Ascierto PA et al (2014) Vemurafenib in patients with BRAF (V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol 15:436–444CrossRefPubMed

Lee D, Porter J, Hertel N et al (2016) Modelling comparative efficacy of drugs with different survival profiles: ipilimumab, vemurafenib and dacarbazine in advanced melanoma. BioDrugs 30:307–319CrossRefPubMed

McArthur GA, Chapman PB, Robert C et al (2014) Safety and efficacy of vemurafenib in BRAF (V600E) and BRAF (V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 15:323–332CrossRefPubMedPubMedCentral

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) (2017) Melanoma. Version I. https://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf. Accessed 10 November 2016

Queirolo P, Spagnolo F, Ascierto PA et al (2014) Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neuro-oncol 118:109–116

Sileni VC, Pigozzo J, Ascierto PA et al (2014) Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. J Exp Clin Cancer Res 33:30CrossRef

Spagnolo F, Picasso V, Lambertini M et al (2016) Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: a systematic review. Cancer Treat Rev 45:38–45CrossRefPubMed

Stokes WA, Lentsch EJ (2014) Age is an independent poor prognostic factor in cutaneous head and neck melanoma. Laryngoscope 124:462–465CrossRefPubMed

Svedman FC, Pillas D, Taylor A et al (2016) Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe—a systematic review of the literature. Clin Epidemiol 8:109–122CrossRefPubMedPubMedCentral

Therneau TM, Grambsch PM (2000) Modeling survival data: extending the cox model. Springer, New YorkCrossRef

Therneau T (2017) A package for survival analysis in S. version 2.38. https://CRAN.R-project.org/package=survival

Ugurel S, Loquai C, Kähler K et al (2015) A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival. Ann Oncol 26:573–582CrossRefPubMed

Titel: Survival of melanoma patients treated with novel drugs: retrospective analysis of real-world data
verfasst von: Marta Polkowska
Paweł Ekk-Cierniakowski
Edyta Czepielewska
Wojciech Wysoczański
Wojciech Matusewicz
Małgorzata Kozłowska-Wojciechowska
Publikationsdatum: 12.06.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 10/2017
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-017-2453-z

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Survival of melanoma patients treated with novel drugs: retrospective analysis of real-world data